Genetic Signatures

Genetic Signatures Financial Leverage

The Financial Leverage (Equity Multiplier) of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is 1.08. In the previous year, Financial Leverage (Equity Multiplier) was 1.09 — a change of -1.29% (lower).

Financial Leverage

1.08

YoY

-1.29%

Last updated:

Financial Leverage (Equity Multiplier) of Genetic Signatures is 2026 1.08 . Financial Leverage (Equity Multiplier) of Genetic Signatures was 2025 1.09 . It decreases by -1.29% lower compared to the previous year.

The Genetic Signatures Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
1.15 AUD
Jan 1, 2020
1.08 AUD
Jan 1, 2021
1.10 AUD
Jan 1, 2022
1.09 AUD
Jan 1, 2023
1.14 AUD
Jan 1, 2024
1.10 AUD
Jan 1, 2025
1.09 AUD
Jan 1, 2026
1.08 AUD
The Genetic Signatures Financial Leverage history
YEARFinancial LeverageYoY
1.08-1.29%
1.09-0.96%
1.10-3.71%
1.14+5.06%
1.09-0.63%
1.10+1.20%
1.08-5.69%
1.15+5.27%
1.09+1.69%
1.07-15.86%
1.27+15.29%
1.11+8.06%
1.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

Financial Leverage (Equity Multiplier) of Genetic Signatures is 1.08 in 2026.

Financial Leverage (Equity Multiplier) of Genetic Signatures changed from 1.09 to 1.08, representing a -1.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Genetic Signatures

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Genetic Signatures